Attribution 4.0 International (CC BY 4.0)2022-11-092022-11-092022-08-09Shen, C., Rashiwala, L., Wiener, R. C., Findley, P. A., Wang, H., & Sambamoorthi, U. (2022). The association of COVID-19 vaccine availability with mental health among adults in the United States. Frontiers in psychiatry, 13, 970007. https://doi.org/10.3389/fpsyt.2022.9700071664-0640https://hdl.handle.net/20.500.12503/31902Objective: To assess whether COVID-19 vaccine approval and availability was associated with reduction in the prevalence of depression and anxiety among adults in the United States. Methods: We adopted cross sectional and quasi-experimental design with mental health measurements before vaccine availability (June 2020, N = 68,009) and after vaccine availability (March 2021, N = 63,932) using data from Census Pulse Survey. Depression and anxiety were derived from PHQ-2 and GAD-2 questionnaires. We compared rates of depression and anxiety between June 2020 and March 2021. Unadjusted and adjusted analysis with replicate weights were conducted. Results: Depression prevalence was 25.0% in June 2020 and 24.6% in March 2021; anxiety prevalence was 31.7% in June 2020 and 30.0% in March 2021 in the sample. In adjusted analysis, there were no significant differences in likelihood of depression and anxiety between June 2020 and March 2021. Conclusion: Depression and anxiety were not significantly different between June 2020 and March 2021, which suggests that the pandemic effect continues to persist even with widespread availability of vaccines.http://creativecommons.org/licenses/by/4.0/Covid-19Census pulse surveyanxietydepressionvaccine availabilityArticle© 2022 Shen, Rashiwala, Wiener, Findley, Wang and Sambamoorthi.13